According to Market Scope’s forecast of the glaucoma surgical device market through 2030, its 4 core categories—microstents, subconjunctival shunts, canal surgery devices, and tube shunts—are “entering a period of rapid evolution,” with next-generation subconjunctival shunts expected to show the greatest growth.

The newly published “2025 Glaucoma Surgical Device Market Report,” finds that all 4 categories will expand, but the most disruptive change will come from next-generation subconjunctival shunts, which proponents say deliver trab- or tube-level intraocular pressure (IOP) reduction without the complications and intensive aftercare of traditional surgery. Microstents, however, will “remain the anchor of the market," as manufacturers continue to push for regulatory approvals and reimbursement in international markets.

According to the report, canal surgery devices are advancing also, thanks to continued innovation. Market Scope states that the products are increasingly being combined with microstents, reinforcing the role of canal-based surgery in comprehensive glaucoma management. 

Growth in tube shunts is expected to be modest compared with the other segments, but the report anticipates that they will continue to play a vital role in managing advanced disease thanks to ongoing improvements.